⌕
Resmed · RMD · NYSE
Tenet 65 · Solid
Compare
$238.93−0.25%At closeTenet 65 · Solid
$238.93−0.60 (−0.25%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$238.96+0.03 (+0.01%)
After hours: Nov 16, 2026, 6:56 PM ET

Resmed (RMD) Earnings Forecast

Analysts expect Resmed (RMD) to earn $12.14 a share in FY27, the average of 15 estimates as of Nov 13, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

FY27 consensus EPS
$12.14
15 analysts
FY28 consensus EPS
$13.25
14 analysts · low $13.05, high $13.78
EPS revisions, 30 days
+0.3%
$12.10 to $12.14
Disagreement, FY27
1.2%
high to low, $12.09 to $12.23

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 13, 2026 · we check it nightly

Analysts expect Resmed to earn $15.48 a share in FY30, growing about 8% a year; 7 analysts publish an estimate for FY30.

Forward P/E · FY27E
19.7×
$239.53 (as of close, Nov 13, 2026) ÷ $12.14 consensus EPS
Coverage · FY27
15 · 22
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY27 EPS consensus is $12.14, up 0.6% in 91 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 91 days. One step per nightly change.

−0.4%+0.2%+0.8%FY27 +0.6%FY28 −0.1%Aug 15Nov 13
EPS30 days90 daysshown aboveSince Jul 2
FY2715 analysts▲ +0.3%$12.10 to $12.14▲ +0.6%$12.06 to $12.14▼ −0.8%$12.23 to $12.14
FY2814 analysts▼ −0.4%$13.30 to $13.25▼ −0.1%$13.26 to $13.25▼ −0.1%$13.26 to $13.25
Sep '269 analysts▲ +0.2%$2.68 to $2.69▼ −5.4%$2.84 to $2.69▼ −6.3%$2.87 to $2.69
Dec '269 analysts▼ −1.3%$3.03 to $2.99▼ −1.5%$3.04 to $2.99▼ −1.5%$3.04 to $2.99

Contributors at both ends of the window: FY27 6 and 15. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 13, 2026 · consensus as of Nov 13, 2026

At 21.6 times earnings, which is what Resmed trades at today, the FY28 consensus of $13.25 works out to $286 a share.

Consensus EPS · FY28
$13.25
14 analysts · low $13.05, high $13.78 · thin coverage
Multiple · today's trailing P/E
21.6×
$239.53 (as of close, Nov 13, 2026) ÷ $11.11, the last four reported quarters, including EPS computed by Tenet
×
Receipt · RMD · FY28Nov 13, 2026
Implied, a share
$286

Range on the low and high estimate: $281 to $297.

$281 low$297 high
13.25 × 21.6, to the dollar
Drag the multipleShaded: where Resmed's P/E sat at each fiscal year end, FY09 to FY26. Each dot is one year.
20×30×40×50×60×
today 21.6×5-yr avg 29.8×10-yr median 37.7×$286 a share

Each point on the line is a multiple, and the flag is the price it implies for FY28. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 19.7 times the FY27 consensus for earnings the Street expects to grow about 9% a year to FY29. That is 2.1 times the growth rate.Show today's multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY09 to FY26 · over 18 fiscal years. The mark is the median of the last 10.
21.6× today
18.3× low76.1× high
37.7× median
Forward 19.7× is a different measure, so it is not placed on a trailing record. Today's mark is the trailing 21.6×, on the same basis as every year behind it.

How much do analysts disagree?

For FY30, estimates run from $14.92 to $16.10 around an average of $15.48, drawn by 7 analysts.

FY27E15 analysts
$12.09 to $12.23 · 1.2%
FY28E14 analysts
$13.05 to $13.78 · 5.5%
FY29E11 analysts
$12.79 to $16.02 · 22.3%
FY30E7 analysts
$14.92 to $16.10 · 7.6%

The dashed line is FY26 filed $10.43, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.

Is next quarter a high bar or an easy one?

Analysts expect Resmed to earn $2.99 a share in the December quarter, the average of 9 estimates. Results are expected by Jan 27, 2027. Last quarter, which ended in September, Resmed earned $2.92 a share. Analysts had expected $2.69, so it came in 8.7% higher.

$2.68
$2.99high $3.09
low $2.95
+11.7%crosses bases
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 9 analysts
Expected report
Jan 27, 2027
Expected by Jan 27. An estimate, not a date the company has set. Companies move it.
Revenue expected · December quarter
$1,455.3M
10 analysts, 1,445.3 to 1,475.3 in $M · 1,422.8 in the same quarter a year ago

The step from a filed quarter to a consensus crosses bases: the filed figure is the company's own GAAP number and the consensus is on the Street's basis. It is printed with both bases named, not as growth. For the March quarter, analysts expect $3.05 a share.

Does Resmed usually beat or miss?

So far we have checked 5 quarters, of which 1 came in above the estimate we held. We add a quarter to this record each time Resmed reports. The next report is expected by Jan 27, 2027.

We started recording estimates on Jul 2, 2026, so quarters that reported before that date cannot be checked.

Before our record
Dec '24
Mar '25
Jun '25
Our record, one quarter per report
−5.8%
Sep '25reaction
−2.1%
−2.4%
Dec '25reaction
+0.3%
−2.0%
Mar '26reaction
−4.1%
−8.9%
Jun '26reaction
−6.3%
+8.7%
Sep '26reaction
−9.1%
reportsJan 27
Dec '26
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Checked so far
5 quarters
one more every report
Beat expectations
1 of 5
full details on the Earnings tab
Share price reaction
Not held
we hold no measured reaction for the quarters we have checked
Typical gap vs estimate
−2.4%
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Resmed on Jul 2, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact. Sep '25, Dec '25, Mar '26 are drawn hollow: we hold no estimate for those quarters recorded strictly before the report, so it is scored against the last estimate we hold rather than the night-before one.

The Street expects sales to grow 6.2% in FY28 and EPS 9.2%. Most of it is sales: the net margin moves from 30.2% to 31.4%, and the implied share count from about 145M to 147M, so these numbers assume no buyback.Show the decomposition and the margin ladderHide the decomposition
FY28 EPS growth, in points
Revenue growth+6.3
Net margin change+4.1
Share count change−1.2
EPS growth+9.2
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
15 analysts publish an EPS estimate for FY27 and 22 publish revenue. Coverage thins with distance: 7 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
2215
FY27E
2114
FY28E
2211
FY29E
197
FY30E
The FY27 panel held 7 analysts when our record of it began on Jul 2, 2026 and holds 15 tonight.

The full consensus, year by year

Consensus as of Nov 13, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
4.05.77.4historyStreet forecastFY23FY26FY30E

Coverage thins with distance: 22 revenue estimates for FY27, 19 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
5.4910.9916.50historyStreet forecastFY23FY26FY30E

Out-year bands widen as fewer analysts publish: 15 EPS estimates for FY27, 7 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY26Filed5.7—10.43————as filed21.6×
FY27E5.85.8 to 5.9▲3.1%a12.1412.09 to 12.23▲16.4%a2.41.80.1522 · 1519.7×
FY28E6.26.1 to 6.3▲6.2%13.2513.05 to 13.78▲9.2%2.61.90.1521 · 1418.1×
FY29E6.66.2 to 7.0▲6.4%14.5012.79 to 16.02▲9.4%2.72.00.1422 · 1116.5×
FY30E7.16.9 to 7.3▲7.1%15.4814.92 to 16.10n/cb3.02.20.1419 · 715.5×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 15 EPS estimates for FY27, 22 for revenue. Not investment advice.

What do analysts expect Resmed to earn in FY27?

Analysts expect Resmed to earn $12.14 a share in FY27, the average of 15 estimates as of Nov 13, 2026.

What is Resmed's earnings forecast for FY28?

The FY28 consensus for Resmed is $13.25 a share from 14 analysts, with a low of $13.05 and a high of $13.78, as of Nov 13, 2026.

Have analysts raised Resmed's earnings estimates?

Resmed's FY27 EPS consensus rose 0.6% in 91 days, from $12.06 to $12.14, as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.